Global Ropivacaine Market Size, Share and Trends Analysis Report, By Application (Surgical Anesthesia, Major Nerve Block, and Labor Pain), By End-User (Hospital, Specialty Clinics, and Ambulatory Surgical Centers), Forecast Period (2022-2028)

The global ropivacaine market is anticipated to grow at a CAGR of 3.4% during the forecast period (2022-2028). Due to changes in pharmacodynamics associated with age and organ function, the aged population is also at a higher risk of suffering organ failure. Patients are at greater risk of heart and lung illness, impaired kidney and liver function, and respiratory and urinary tract issues as the proportion of elderly patients grow. The overall increase in surgical procedures will have a significant impact on the market for anesthetic medications.

Ropivacaine is a local anesthetic that is used to give surgical anesthesia and analgesia for longer periods of time. It is a synthetic ester of ropivacaine hydrochloride that has a longer duration of action than other agents, making it the most reliable agent for delivering local anesthetic for outpatient treatments. Other advantages include a lower necessary concentration, improved penetration, and lesser toxicity. Since it reduces allergies and systemic adverse effects, it is frequently used in spinal anesthesia. Ropivacaine inhibits sensory transmission at all levels, including somatic, visceral, and sympathetic reflexes. Reducing the need for augmentation or supplementing drugs, enhances the quality of epidural analgesia during childbirth.

During the projection period, the segment is predicted to develop due to an increase in the number of surgical procedures performed around the globe and convenient availability. Since ropivacaine has low toxic effects, adequate analgesic effectiveness, and a favorable pharmacokinetic profile, it has a lot of potential for therapeutic development. When used for epidural anesthesia, ropivacaine, an amide-type local anesthetic, has been demonstrated to provide larger safety margins than bupivacaine. When utilized in clinical research, the chemical has been demonstrated to have less than 15% vasodilatory effects.

Some major players in the market include Akorn Operating Company LLC, Apin Chemicals Ltd., NAVINTA LLC, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnership, collaborations, and new product launches, to stay competitive in the market.

Company and its Products

• Pfizer, Inc. offers ROPIVACAINE HYDROCHLORIDE, which is a local anesthetic. It works by preventing pain signals from reaching the brain through the nerves. This aids in the reduction of pain sensations.
• Akorn Operating Company LLC offers Naropin, a ropivacaine hydrochloride injection, Naropin is a prescription drug that is used as an anesthetic or to relieve labor pains. Naropin can be taken alone or in combination with other drugs.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-Use
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Akorn Operating Company LLC, Apin Chemicals Ltd., NAVINTA LLC, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ropivacaine Market Report by Segment

By Application

• Surgical Anesthesia
• Major Nerve Block
• Labor Pain

By End-Use

• Hospital
• Speciality Clinics
• Ambulatory Surgical Centers

Global Ropivacaine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa